BioMarin Announces First Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- Wall Street ends down as US-Iran peace optimism fades
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Wall Street ends down as US-Iran peace optimism fades
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Goldman Sachs Remains Bullish on BioMarin Pharma (BMRN) Following 1Q
April 26, 2018 8:12 AM EDTGoldman Sachs reiterated a Buy rating and $132.00 price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) following the company's 1Q earnings release. BMRN reported total revenue of $373.4mn, above FactSet consensus of $349mn, driven primarily by the adoption of the new revenue recognition principle for... More
BioMarin Pharma (BMRN) Misses Q1 EPS by 8c
April 25, 2018 4:06 PM EDTBioMarin Pharma (NASDAQ: BMRN) reported Q1 EPS of ($0.26), $0.08 worse than the analyst estimate of ($0.18). Revenue for the quarter came in at $373.4 million versus the consensus estimate of $348.57 million.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
... More